Types of topical treatment for peripheral neuropathic pain. Mechanism of action and indications

被引:0
作者
Mahn, F. [1 ]
Baron, R. [1 ]
机构
[1] Univ Klinikum Schleswig Holstein, Sekt Neurol, D-24105 Kiel, Germany
来源
SCHMERZ | 2010年 / 24卷 / 04期
关键词
Peripheral neuropathic pain syndromes; Partial nerve lesion; Topical; Lidocaine; Capsaicin; CONCENTRATION CAPSAICIN PATCH; GATED SODIUM-CHANNELS; TOXIN TYPE-A; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; BOTULINUM TOXIN; PROTEIN EXPRESSION; CONTROLLED-TRIAL; LIDOCAINE; AMITRIPTYLINE;
D O I
10.1007/s00482-010-0939-6
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The term "peripheral neuropathic pain syndromes" summarizes several chronic pain syndromes, which can occur focally or generalized in the peripheral nervous system in the course of an impairment of afferent neurons. Controlled clinical trials gave distinct indications for systemic treatments with antidepressants, anticonvulsants and opioid analgesics in several neuropathic pain syndromes. In addition to these systemic therapies, there are also two topical treatment options: topical application of lidocaine and capsaicin. An important cause of sensitization phenomena of afferent nociceptors is the upregulation of sodium channels and thermosensor channels. In the context of a partial nerve lesion that leaves behind partially preserved or regenerated afferent nerve fibres, just these channels could be used as target structures for topical medications. Topically applied drugs are absorbed systemically only in minute quantities, so systemic side effects are negligible. Pharmacological interactions with systematically acting substances are also virtually absent; thus, topically applied substances are especially appropriate for add-on therapy in addition to systemic pain medication.
引用
收藏
页码:317 / +
页数:8
相关论文
共 51 条
[1]  
Amir R, 1999, J NEUROSCI, V19, P8589
[2]   Future aspects of botulinum neurotoxins [J].
Aoki, K. R. .
JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (04) :567-573
[3]   EFNS guidelines on pharmacological treatment of neuropathic pain [J].
Attal, N. ;
Cruccu, G. ;
Haanpaa, M. ;
Hansson, P. ;
Jensen, T. S. ;
Nurmikko, T. ;
Sampaio, C. ;
Sindrup, S. ;
Wiffen, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (11) :1153-1169
[4]   NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study (vol 7, pg 1106, 2008) [J].
Backonja, M. ;
Wallace, M. S. ;
Blonsky, E. R. .
LANCET NEUROLOGY, 2009, 8 (01) :31-31
[5]   Mechanisms of Disease: neuropathic pain - a clinical perspective [J].
Baron, R .
NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (02) :95-106
[6]  
BARON R, 2009, NEUROPATHIC PAIN CLI
[7]  
BARON R, 2005, LEITLINIEN DIAGNOSTI, pS531
[8]   Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy [J].
Baron, Ralf ;
Mayoral, Victor ;
Leijon, Goeran ;
Binder, Andreas ;
Steigerwald, Ilona ;
Serpell, Michael .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) :1677-1687
[9]   TOPICAL CAPSAICIN TREATMENT OF CHRONIC POSTHERPETIC NEURALGIA [J].
BERNSTEIN, JE ;
KORMAN, NJ ;
BICKERS, DR ;
DAHL, MV ;
MILLIKAN, LE .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 21 (02) :265-270
[10]   Impaired nociception and pain sensation in mice lacking the capsaicin receptor [J].
Caterina, MJ ;
Leffler, A ;
Malmberg, AB ;
Martin, WJ ;
Trafton, J ;
Petersen-Zeitz, KR ;
Koltzenburg, M ;
Basbaum, AI ;
Julius, D .
SCIENCE, 2000, 288 (5464) :306-313